MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-07-2022
Concert Pharmaceuticals Retained Earnings 2011-2025 | CNCE
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Concert Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -349 M | -269 M | -195 M | -117 M | -76.2 M | -172 M | -121 M | -145 M | -114 M | -108 M | -87.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -76.2 M | -349 M | -159 M |
Quarterly Retained Earnings Concert Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -440 M | - | -387 M | -349 M | -313 M | -287 M | -292 M | -269 M | -269 M | -269 M | -269 M | -195 M | -195 M | -195 M | -195 M | -117 M | -117 M | -117 M | -117 M | -76.2 M | -76.2 M | -76.2 M | -76.2 M | -172 M | -172 M | -172 M | -172 M | -121 M | -121 M | -121 M | -121 M | -145 M | -145 M | -145 M | -145 M | -114 M | -114 M | -114 M | -114 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -76.2 M | -440 M | -182 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Pharming Group N.V.
PHAR
|
-257 M | $ 17.91 | -1.0 % | $ 7.59 B |  Niderland |
 |
InflaRx N.V.
IFRX
|
-168 M | $ 1.09 | -4.82 % | $ 152 M | Germany |
 |
Alpine Immune Sciences
ALPN
|
-224 M | - | - | $ 2.17 B |  USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M |  France |
 |
Aptorum Group Limited
APM
|
-72.4 M | $ 1.15 | -1.71 % | $ 6.27 M |  China |
 |
Arbutus Biopharma Corporation
ABUS
|
-1.28 B | $ 4.78 | -0.31 % | $ 793 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-903 M | $ 3.03 | -0.49 % | $ 234 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-972 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-223 M | - | 1.93 % | $ 17.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
AlloVir
ALVR
|
-715 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-611 M | $ 209.39 | -1.61 % | $ 5 B |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
-243 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-366 M | - | - | $ 10.1 M | USA |
 |
Aptevo Therapeutics
APVO
|
-248 M | $ 0.6 | -35.8 % | $ 166 K | USA |
 |
Avenue Therapeutics
ATXI
|
-103 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-1.1 B | $ 1.66 | -1.49 % | $ 424 M | Britain |
 |
AVROBIO
AVRO
|
-477 M | - | 1083.1 % | $ 745 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-182 M | $ 3.12 | 0.81 % | $ 7.51 B |  Australia |
 |
BioDelivery Sciences International
BDSI
|
-256 M | - | -4.8 % | $ 255 M | USA |
 |
Athersys
ATHX
|
-583 M | - | 3.77 % | $ 22.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
BioVie
BIVI
|
-352 M | $ 1.2 | -5.51 % | $ 1.77 M | USA |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-575 M | - | -9.72 % | $ 5.89 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-166 M | $ 0.22 | 24.46 % | $ 479 M |  Israel |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-1.02 B | - | -15.15 % | $ 60.3 M | Britain |
 |
Berkeley Lights
BLI
|
-362 M | - | -7.31 % | $ 87 M | USA |
 |
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
-410 M | $ 94.72 | -0.33 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
569 M | $ 27.09 | 1.04 % | $ 1.31 B | USA |
 |
BeiGene, Ltd.
BGNE
|
-8.61 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
-491 M | - | -10.95 % | $ 876 K | USA |
 |
Anika Therapeutics
ANIK
|
128 M | $ 9.6 | 1.27 % | $ 141 M | USA |
 |
bluebird bio
BLUE
|
-4.26 B | - | - | $ 546 M | USA |
 |
Zai Lab Limited
ZLAB
|
-2.45 B | $ 18.4 | -0.97 % | $ 18.2 B | China |
 |
Catalyst Biosciences
CBIO
|
-85.5 M | $ 12.33 | -0.29 % | $ 812 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-2.12 B | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M | USA |
 |
Axon Enterprise
AXON
|
812 M | $ 584.81 | -1.07 % | $ 44.3 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-149 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-334 M | $ 2.44 | -3.56 % | $ 15.3 M | USA |
 |
AstraZeneca PLC
AZN
|
5.3 B | $ 92.79 | 0.37 % | $ 96.9 B | Britain |
 |
ChromaDex Corporation
CDXC
|
-182 M | - | -0.88 % | $ 598 M | USA |
 |
Certara
CERT
|
-128 M | $ 8.9 | -0.17 % | $ 1.43 B | USA |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |